Femoral Neck FracturesFASTER-HIPNCT07244211
MAPT Protocol: Fixation Versus Arthroplasty Surgical Treatments for Early Recovery After HIP Fracture (FASTER-HIP)
A study testing Hip arthroplasty and Internal fixation in people with Femoral Neck Fractures, run by University of Southern California at 31 sites in 5 countries.
Trial summary
This study is an intervention domain of the Musculoskeletal Adaptive Platform Trial. The primary goal of this pragmatic, randomized, open-label, comparative effectiveness trial is to evaluate if arthroplasty is superior to internal fixation when used to treat minimally displaced femoral neck fractures in older adults… Read more about this study
- Who is it for?
- Ages 60 years and older
- Conditions the study is for
- Femoral Neck Fractures
- What is being tested?
- Hip arthroplasty and Internal fixation
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 600 participants
- Where
- 31 sitesin 5 countries
- Study dates
- 23 Jan 2026to 31 Jan 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 60 years of age or older undergoing surgery due to a minimally displaced femoral neck fracture
- The patient has a health condition affecting physical mobility.
- Complete fracture of the femoral neck (AO/OTA 31B) confirmed with anteroposterior and lateral hip radiographs, computed tomography, or magnetic resonance imaging.
- Minimally displaced fracture that could be, in the judgment of the attending surgeon, managed with either arthroplasty or in situ internal fixation without reduction.
- Low energy injury mechanism.
- Surgeons with expertise in internal fixation and total hip arthroplasty or hemiarthroplasty are available to perform surgery.
Who cannot join
- The patient is not clinically suitable for either compared treatment.
- Expected injury survival of less than 12 months.
- Terminal illness with expected survival of less than 12 months.
- Incarceration.
- Unable to obtain informed consent due to language barriers.
- Unable to obtain informed consent because the legally authorized representative was unavailable.
Show all 19Show fewer
- Problems, in the judgment of the study personnel, with maintaining follow-up with the patient.
- Currently enrolled in a study or intervention domain that does not permit co-enrollment.
- Prior enrollment in the specific platform trial intervention domain.
- Patient or legally authorized representative did not provide informed consent (declined participation).
- Eligible patient or legally authorized representative was not approached within the screening window (missed participant).
- Other reasons to exclude the patient, as approved by the data coordinating center.
- Associated lower extremity injury that prevents post-operative weight-bearing.
- Retained hardware around the hip that precludes either study treatment.
- Infection around the hip (soft tissue or bone).
- Pathologic fracture with a lytic lesion in the femoral neck that precludes internal fixation.
- Injury did not occur within 21 days of screening.
- Patient is too ill, in the judgment of the attending surgeon, for internal fixation.
- Patient is too ill, in the judgment of the attending surgeon, for arthroplasty.
Trial locations and contacts
31 sites in 5 countries. Contact the study team or a site near you to ask about taking part.
31 sites in 5 countries
United States21 sites, 21 recruiting
- Recruiting
St. Luke's University Health System
Allentown, Pennsylvania, 18102
Dustin Greenhill, MD, dustin.greenhill@sluhn.org
Dustin Greenhill, MD
- Recruiting
University of Maryland, Baltimore - R Adams Cowley Shock Trauma Center
Baltimore, Maryland, 21201
Mark Gage, MD, mgage@som.umaryland.edu
Mark Gage, MD
- Recruiting
Indiana University
Bloomington, Indiana, 47405
Dillon O'Neill, MD, doneill5@iuhealth.org
Dillon O'Neill, MD
- Not yet recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215
Ishaq Ibrahim, MD, ioibrahi@bidmc.harvard.edu
Ishaq Ibrahim, MD
- Not yet recruiting
University of Vermont
Burlington, Vermont, 05405
Michael Blankstein, MD, michael.blankstein@uvmhealth.org
Michael Blankstein, MD
- Recruiting
University of Cincinnati
Cincinnati, Ohio, 45221
Michael Beltran, MD, beltrame@ucmail.uc.edu
Michael Beltran, MD
- Recruiting
Inova Health Care Services
Fairfax, Virginia, 22031
Grag Gaski, MD, greg.gaski@inova.org
Greg Gaski, MD
- Recruiting
Prisma Health-Upstate
Greenville, South Carolina, 29601
Kyle Jeray, MD, kyle.jeray@prismahealth.org
Kyle Jeray, MD
- Recruiting
University of California, Irvine
Irvine, California, 92660
Gerard Slobogean, MD, 714-456-1699, gsloboge@hs.uci.edu
Gerard Slobogean, MD
- Recruiting
University of Maryland Capital Region Health
Largo, Maryland, 20774
Todd Jaeblon, MD, tjaeblon@som.umaryland.edu
Todd Jaeblon, MD
- Recruiting
Los Angeles General Medical Center
Los Angeles, California, 90033
Joshua Gary, MD, +13234426984, OrthoTraumaResearch@med.usc.edu
Joshua L Gary, MD
- Recruiting
University of Southern California
Los Angeles, California, 90033
Joshua Gary, MD, +13234426984, OrthoTraumaResearch@med.usc.edu
Joshua L Gary, MD
- Recruiting
Cedars-Sinai Medical Center
Los Angeles, California, 90048
Carol Lin, MD, carol.lin@cshs.org
Carol Lin, MD
- Recruiting
University of Wisconsin - Madison
Madison, Wisconsin, 53706
Chris Domes, MD, domes@ortho.wisc.edu
Chris Domes, MD
- Not yet recruiting
University of Miami
Miami, Florida, 33146
Giselle Hernandez, MD, g.hernandez@med.miami.edu
Giselle Hernandez, MD
- Recruiting
Vanderbilt University
Nashville, Tennessee, 37235
Lauren Tatman, MD, lauren.m.tatman@vumc.org
Lauren Tatman, MD
- Recruiting
NYU Langone Health
New York, New York, 10016
Daniel Waren, Daniel.waren@nyulangone.org
Ran Schwarzkopf, MD
- Recruiting
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104
Brandon Hull, MD, Brandon-Hull@ou.edu
Brandon Hull, MD
- Recruiting
University of Utah
Salt Lake City, Utah, 84108
Lucas Marchand, MD, lucas.marchand@hsc.utah.edu
Lucas Marchand, MD
- Recruiting
University of California San Francisco
San Francisco, California, 94143
Saam Morshed, MD, Saam.morshed@ucsf.edu
Saam Morshed, MD
- Recruiting
University of Mississippi
University, Mississippi, 38677
Patrick Bergin, MD, pbergin@umc.edu
Patrick Bergin, MD
Canada4 sites, 4 recruiting
- Recruiting
London Health Sciences Centre
London, Ontario, N6A 5W9,
Emil Schemitsch, MD, emil.schemitsch@lhsc.on.ca
Emil Schemitsch, MD
- Not yet recruiting
The Ottawa Hospital
Ottawa, K1H 8L6
Bradley Meulenkamp, MD, bmeulenkamp@toh.ca
Bradley Meulenkamp, MD
- Recruiting
University of British Columbia
Vancouver, British Columbia, V6T 1Z4
Aresh Sepehri, MD
aresh.sepehri@vch.ca
- Recruiting
Fraser Health Authority
Vancouver, British Columbia
Darius Viskontas, MD, 604-777-5577, dariusviskontas@yahoo.ca
604-777-5577
Spain4 sites, 4 recruiting
- Not yet recruiting
Hospital Universitario Mutua de Terrassa
Barcelona, 08221
Pablo Castillon Bernal, MD, pablocastillon@mutuaterrassa.es
Pablo Castillon Bernal, MD
- Not yet recruiting
Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG)
Barcelona
Alfred Dealbert Dealbert, MD, adealbert@csapg.cat
Alfred Dealbert, MD
- Not yet recruiting
FRCB-IDIBAPS (Hospital Clinic Barcelona)
Barcelona
Pilar Camacho, MD, PCAMACHO@clinic.cat
Pilar Camacho, MD
- Not yet recruiting
Hospital Universitari Vall d'Hebron
Barcelona
Carlos Alberto Piedra-Calle, MD, carlosalberto.piedra@vallhebron.cat
Carlos Alberto Piedra-Calle, MD
Norway1 site, 1 recruiting
- Recruiting
Sykehuset Østfold HF / Østfold Hospital Trust
Grålum, 1714
Frede Frihagen, MD
Frede.Frihagen@so-hf.no
United Kingdom1 site, 1 recruiting
- Not yet recruiting
University of Edinburgh
Edinburgh, EH8 8BG
Andrew Duckworth, MD, andrew.duckworth@ed.ac.uk
About this study
Official title: Musculoskeletal Adaptive Platform Trial (MAPT): Fixation Versus Arthroplasty Surgical Treatments for Early Recovery After HIP Fracture (FASTER-HIP)
This study is an intervention domain of the Musculoskeletal Adaptive Platform Trial. The primary goal of this pragmatic, randomized, open-label, comparative effectiveness trial is to evaluate if arthroplasty is superior to internal fixation when used to treat minimally displaced femoral neck fractures in older adults ≥60 years old. We hypothesize that arthroplasty will reduce death, preserve ambulation, increase days alive and out of hospital, and improve health status compared to internal fixation within 4 months and 12 months from randomization.
Read the detailed description
The Musculoskeletal Adaptive Platform Trial (MAPT) is an adaptive platform trial protocol that enables the simultaneous evaluation of multiple interventions (i.e., intervention domains) within a consistent infrastructure. Each intervention being evaluated in the MAPT will have an intervention domain protocol that describes additional eligibility criteria, interventions, secondary outcomes, and statistical stopping rules. The overarching objective of the MAPT trial platform is to incrementally decrease decisional uncertainty and identify treatments that will optimize patient outcomes. The platform focuses on the comparative effectiveness of available treatment options.
Adult patients aged 60 years or older with a low-energy minimally displaced femoral neck fracture treated with surgery are eligible for the FASTER-HIP intervention domain. Nearly half of all elderly hip fractures are femoral neck fractures, and approximately 20% are minimally displaced. Internal fixation has remained the treatment of choice for these injuries because these fractures can be fixed in situ, and the surgical implants can be inserted with little surgical dissection. Patients treated with internal fixation experience high complication rates, with the pooled risk of reoperation and mortality each above 14%. Preliminary data have suggested arthroplasty for minimally displaced fractures may lead to better patient outcomes, including improved ambulation, fewer reoperations, and a lower risk of death compared to internal fixation. While the preliminary data supporting the use of arthroplasty for minimally displaced fractures is promising, the necessary evidence to make this practice change remains lacking.
FASTER-HIP is a pragmatic, randomized, open-label, comparative effectiveness trial comparing hip arthroplasty versus internal fixation for minimally displaced femoral neck fractures. Randomization in this domain occurs in a 1:1 ratio (hip arthroplasty:internal fixation). The primary outcome is a composite of death within 120 days, ambulation status at 120 days, and days alive and out of hospital within 120 days of randomization. The primary outcome will be hierarchically assessed using the Win ratio. Secondary outcomes include the same composite at 365 days, individual components of the composite, health-related quality of life (EQ-5D-5L), and pain scores during hospitalization.
- Conditions
- Femoral Neck Fractures
- Being tested
- Hip arthroplasty, Internal fixation
- Keywords
- Minimally displaced femoral neck fractures, arthroplasty, hip fractures, femoral fractures, orthopaedic procedures, older adults, patient-centered outcomes, adaptive trial, internal fixation, pragmatic trial
- Medical subject headings
- Femoral Neck Fractures, Hip Fractures, Femoral Fractures
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Hip arthroplastyProcedure or surgery
Participants will undergo surgical treatment using standard hip arthroplasty techniques for femoral minimally displaced femoral neck fracture. A modern porous-coated press-fit or cemented hip arthroplasty prosthesis will be used at the treating surgeon's discretion. Press-fit implants that have no ingrowth or ongrowth surface will not be permitted. The type of hip prosthesis (hemiarthroplasty or total hip arthroplasty), bearing (single or dual mobility), or the method of arthroplasty fixation (cemented or uncemented) will be at the discretion of the treating surgeon.
Internal fixationProcedure or surgery
Participants will undergo surgical treatment using standard fixation techniques for minimally displaced femoral neck fractures. The treating surgeon may perform fracture reduction maneuvers if desired. Fixed-angle devices and multiple screws will be permitted. The internal fixation device(s) will be inserted through a small lateral incision. Internal fixation constructs combining cancellous screws and fixed-angle devices will be permitted.
| Study group | Role | What they receive |
|---|---|---|
| Hip arthroplasty | Active comparator | Not described Receives: Procedure: Hip arthroplasty |
| Internal fixation | Active comparator | Not described Receives: Procedure: Internal fixation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Composite outcome of death, ambulation status, and days alive and out of hospital.
Death consists of time to all-cause mortality.
Ambulation will be evaluated using an ordinal ranking of independence.
Days alive and out of hospital will be calculated by subtracting the sum of days meeting one of two criteria below:
- Days not alive.
- Any day on which the participant had an overnight stay in a hospital, inpatient rehabilitation, skilled nursing facility, nursing home, inpatient mental health care facility, or long-term care facility.
Measured: 120 days after randomization
Secondary outcomes (10)
Composite outcome of death, ambulation status, and days alive and out of hospital.
Death consists of time to all-cause mortality.
Ambulation will be evaluated using an ordinal ranking of independence.
Days alive and out of hospital will be calculated by subtracting the sum of days meeting one of two criteria below:
- Days not alive.
- Any day on which the participant had an overnight stay in a hospital, inpatient rehabilitation, skilled nursing facility, nursing home, inpatient mental health care facility, or long-term care facility.
Measured: 365 days after randomization
Death
Death consists of time to all-cause mortality.
Measured: 120 days post-randomization
Death
Death consists of time to all-cause mortality.
Measured: 12 months post-randomization
Ambulation status
Ambulation will be evaluated using an ordinal ranking of independence
Measured: 120 days post-randomization
Ambulation status
Ambulation will be evaluated using an ordinal ranking of independence
Measured: 12 months post-randomization
Days alive and out of hospital
Days alive and out of hospital will be calculated by subtracting the sum of days meeting one of two criteria below:
- Days not alive.
- Any day on which the participant had an overnight stay in a hospital, inpatient rehabilitation, skilled nursing facility, nursing home, inpatient mental health care facility, or long-term care facility.
Measured: 120 days post-randomization
Days alive and out of hospital
Days alive and out of hospital will be calculated by subtracting the sum of days meeting one of two criteria below:
- Days not alive.
- Any day on which the participant had an overnight stay in a hospital, inpatient rehabilitation, skilled nursing facility, nursing home, inpatient mental health care facility, or long-term care facility.
Measured: 12 months post-randomization
Health-related quality of life
EQ-5D-5L - Range: 0 to 1, Higher scores indicates better self-perceived health
Measured: 120 days days post-randomization
Health-related quality of life
EQ-5D-5L - Range: 0 to 1, Higher scores indicates better self-perceived health
Measured: 12 months post-randomization
Numeric Pain Rating Scale
The highest level of pain recorded daily in the participant's medical record - Range: 0-10, higher score indicates higher level of pain
Measured: During hospitalization in the first seven postoperative days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Nov 2025
- Study start23 Jan 2026
- Primary completion28 Feb 2029 (estimated)
- Study completion31 Jan 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Femoral Neck FracturesStudies of the same condition, open and under way.
- More trials run by University of Southern CaliforniaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 600 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Southern California
- Sponsor type
- University, hospital or other
- Collaborators
- Patient-Centered Outcomes Research Institute, McMaster University, University of Maryland, Baltimore, Evellere Group
- Responsible party
- Principal investigator, Joseph Patterson, University of Southern California
- Investigators
- Joseph T Patterson, MD, Principal investigator, University of Southern California
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07244211
- Sponsor's protocol ID
- BPS-2024C1-37436
- Other IDs
- BPS-2024C1-37436
- Acronym
- FASTER-HIP
- Status last verified
- Jun 2026
- First submitted
- 31 Oct 2025
- Last updated
- 5 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 5 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Musculoskeletal Adaptive Platform Trial (MAPT): Fixation Versus Arthroplasty Surgical Treatments for Early Recovery After HIP Fracture (FASTER-HIP)
- ClinicalTrials.gov ID
- NCT07244211
- Acronym / sponsor ID
- FASTER-HIP / BPS-2024C1-37436
- Conditions
- Femoral Neck Fractures
- Keywords
- Minimally displaced femoral neck fractures, arthroplasty, hip fractures, femoral fractures, orthopaedic procedures, older adults, patient-centered outcomes, adaptive trial
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 600 participants (estimated)
- Lead sponsor
- University of Southern CaliforniaUniversity, hospital or other
- Collaborators
- Patient-Centered Outcomes Research Institute, McMaster University, University of Maryland, Baltimore, Evellere Group
- Study start
- 23 Jan 2026 (actual)
- Primary completion
- 28 Feb 2029 (estimated)
- Study completion
- 31 Jan 2030 (estimated)
- First posted
- 24 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is an intervention domain of the Musculoskeletal Adaptive Platform Trial. The primary goal of this pragmatic, randomized, open-label, comparative effectiveness trial is to evaluate if arthroplasty is superior to internal fixation when used to treat minimally displaced femoral neck fractures in older adults ≥60 years old. We hypothesize that arthroplasty will reduce death, preserve ambulation, increase days alive and out of hospital, and improve health status compared to internal fixation within 4 months and 12 months from randomization.
Detailed description
The Musculoskeletal Adaptive Platform Trial (MAPT) is an adaptive platform trial protocol that enables the simultaneous evaluation of multiple interventions (i.e., intervention domains) within a consistent infrastructure. Each intervention being evaluated in the MAPT will have an intervention domain protocol that describes additional eligibility criteria, interventions, secondary outcomes, and statistical stopping rules. The overarching objective of the MAPT trial platform is to incrementally decrease decisional uncertainty and identify treatments that will optimize patient outcomes. The platform focuses on the comparative effectiveness of available treatment options.
Adult patients aged 60 years or older with a low-energy minimally displaced femoral neck fracture treated with surgery are eligible for the FASTER-HIP intervention domain. Nearly half of all elderly hip fractures are femoral neck fractures, and approximately 20% are minimally displaced. Internal fixation has remained the treatment of choice for these injuries because these fractures can be fixed in situ, and the surgical implants can be inserted with little surgical dissection. Patients treated with internal fixation experience high complication rates, with the pooled risk of reoperation and mortality each above 14%. Preliminary data have suggested arthroplasty for minimally displaced fractures may lead to better patient outcomes, including improved ambulation, fewer reoperations, and a lower risk of death compared to internal fixation. While the preliminary data supporting the use of arthroplasty for minimally displaced fractures is promising, the necessary evidence to make this practice change remains lacking.
FASTER-HIP is a pragmatic, randomized, open-label, comparative effectiveness trial comparing hip arthroplasty versus internal fixation for minimally displaced femoral neck fractures. Randomization in this domain occurs in a 1:1 ratio (hip arthroplasty:internal fixation). The primary outcome is a composite of death within 120 days, ambulation status at 120 days, and days alive and out of hospital within 120 days of randomization. The primary outcome will be hierarchically assessed using the Win ratio. Secondary outcomes include the same composite at 365 days, individual components of the composite, health-related quality of life (EQ-5D-5L), and pain scores during hospitalization.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Hip arthroplasty | Active comparator | Procedure: Hip arthroplasty |
| Internal fixation | Active comparator | Procedure: Internal fixation |
Who may qualify
- Ages
- 60 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- 60 years of age or older undergoing surgery due to a minimally displaced femoral neck fracture
- The patient has a health condition affecting physical mobility.
- Complete fracture of the femoral neck (AO/OTA 31B) confirmed with anteroposterior and lateral hip radiographs, computed tomography, or magnetic resonance imaging.
- Minimally displaced fracture that could be, in the judgment of the attending surgeon, managed with either arthroplasty or in situ internal fixation without reduction.
- Low energy injury mechanism.
Key exclusion criteria (19 listed)
- The patient is not clinically suitable for either compared treatment.
- Expected injury survival of less than 12 months.
- Terminal illness with expected survival of less than 12 months.
- Incarceration.
- Unable to obtain informed consent due to language barriers.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Hip arthroplastyParticipants will undergo surgical treatment using standard hip arthroplasty techniques for femoral minimally displaced femoral neck fracture. A modern porous-coated press-fit or cemented hip arthroplasty prosthesis will be used at the treating surgeon's discretion. Press-fit implants that have no ingrowth or ongrowth surface will not be permitted. The type of hip prosthesis (hemiarthroplasty or total hip arthroplasty), bearing (single or dual mobility), or the method of arthroplasty fixation (cemented or uncemented) will be at the discretion of the treating surgeon. | Procedure or surgery | Hip arthroplasty |
| Internal fixationParticipants will undergo surgical treatment using standard fixation techniques for minimally displaced femoral neck fractures. The treating surgeon may perform fracture reduction maneuvers if desired. Fixed-angle devices and multiple screws will be permitted. The internal fixation device(s) will be inserted through a small lateral incision. Internal fixation constructs combining cancellous screws and fixed-angle devices will be permitted. | Procedure or surgery | Internal fixation |
Primary outcome
Composite outcome of death, ambulation status, and days alive and out of hospital.
Time frame: 120 days after randomization
Death consists of time to all-cause mortality. Ambulation will be evaluated using an ordinal ranking of independence. Days alive and out of hospital will be calculated by subtracting the sum of days meeting one of two criteria below: * Days not alive. * Any day on which the participant had an overnight stay in a hospital, inpatient rehabilitation, skilled nursing facility, nursing home, inpatient mental health care facility, or long-term care facility.
10 secondary outcomes
Composite outcome of death, ambulation status, and days alive and out of hospital.
Time frame: 365 days after randomization
Death
Time frame: 120 days post-randomization
Death
Time frame: 12 months post-randomization
Ambulation status
Time frame: 120 days post-randomization
Ambulation status
Time frame: 12 months post-randomization
Days alive and out of hospital
Time frame: 120 days post-randomization
Days alive and out of hospital
Time frame: 12 months post-randomization
Health-related quality of life
Time frame: 120 days days post-randomization
Health-related quality of life
Time frame: 12 months post-randomization
Numeric Pain Rating Scale
Time frame: During hospitalization in the first seven postoperative days
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Oct 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Femoral Neck Fractures
Not yet recruiting
Lumbar Erector Spinae Plane Block Versus PENG Block for Hip Fracture Surgery
Femur Neck Fracture, Hip Fractures
Active, not recruiting
Lumbar-Sacral Plexus Block vs Fascia Iliaca Block Plus Low-Dose Spinal Anesthesia for Femoral Neck Fracture Surgery
Femoral Neck Fractures, Nerve Block
Active, not recruitingPhase 2
BDSF Vs DHS With Anterotational Screw in Vertical FNF
Evaluation of BDSF in FNF
RecruitingObservational study
Z1 Hip System: Post-Market Clinical Follow Up Study
Hip Osteoarthritis, Acute Traumatic Fracture of the Femoral Head or Neck
Not yet recruiting
Trochanteric Bursa Repair and Lateral Hip Pain After Hemiarthroplasty for Femoral Neck Fracture
Femoral Neck Fracture
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Joseph T Patterson, MD principal investigator
University of Southern California
31 sites in 5 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Hip arthroplasty and Internal fixation in people with Femoral Neck Fractures, run by University of Southern California at 31 sites in 5 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 5 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 31 sites in United States, Canada, Spain, Norway, United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Joseph Patterson, MD (+13234426984, OrthoTraumaResearch@med.usc.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Composite outcome of death, ambulation status, and days alive and out of hospital. (time frame: 120 days after randomization). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Oct 2026.